EGFR and esophageal squamous cell carcinoma: Erlotinib and gefitinib are also specific EGFR TKIs, and once-weekly paclitaxel combined with erlotinib and concurrent RT is expected to be an effective and tolerated regimen for patients with unresectable locally advanced ESCC [110], while gefitinib and concurrent RT are effective and tolerated in elderly ESCC patients [111].